Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911
March 28, 2019
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor
|Re:||Adial Pharmaceuticals, Inc.|
|Registration Statement on Form S-1, as amended|
|File No: 333-230470|
Dear Mr. Gabor:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-230470), be accelerated by the U.S. Securities and Exchange Commission to Monday, April 1, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|Very truly yours,|
|ADIAL PHARMACEUTICALS, INC.|
|By:||/s/ William B. Stilley III|
B. Stilley III|
Chief Executive Officer
Joseph Truluck, Chief Financial Officer, Adial Pharmaceuticals, Inc.
Leslie Marlow, Esq., Gracin & Marlow, LLP